scholarly journals Nested variant of urothelial carcinoma of the urinary bladder

Rare Tumors ◽  
2011 ◽  
Vol 3 (4) ◽  
pp. 132-134 ◽  
Author(s):  
Tadashi Terada
Keyword(s):  
Urothelial Carcinoma ◽  
Lamina Propria ◽  
Bladder Tumor ◽  
Clinical Course ◽  
Carcinoma Cells ◽  
Ki 67 ◽  
Atypical Cells ◽  
Nested Variant ◽  
Aggressive Clinical Course ◽  
Nephrogenic Metaplasia

The nested variant of urothelial carcinoma (NVUC) is characterized by the presence of benign-appearing urothelial carcinoma cells in the lamina propria, sparing the surface urothelial involvement. NVUC shows aggressive clinical course despite of benign-looking histology. Herein reported are two cases of NVUC. One is 80-year-old woman, and another is 78-year-old man. In both cases, atypical cells forming nests and tubules were seen in the lamina propria without surface urothelial involvement. One case resembled nephrogenic metaplasia and another proliferated Brunn's nest or inverted papilloma. Immunohistochemically, both cases showed positive p53 and high Ki67 labeling, suggesting that both cases are malignant. Immunohistochemically, one case was characterized by positive cytokeratins, EMA, p53, Ki-67 (labeling=15%), α-methylacyl CoA racemase, CA19-9, and MUC1, and another case by positive cytokeratins, EMA, p63, p53, Ki-67 (lebeling=30%), CD10, CEA, and MUC1. Cyto keratin immunoprofiles were described and other antigens’ expressions were shown. The patients are now free of tumor 6 and 15 months after the resection of the bladder tumor.

The Nested Variant of Urothelial Carcinoma: Clinicopathology of 2 Cases

2003 ◽  
Vol 127 (8) ◽  
pp. e333-e336 ◽  
Author(s):  
Guang-Qian Xiao ◽  
Stephen J. Savage ◽  
Michael E. Gribetz ◽  
David E. Burstein ◽  
Lorraine K. Miller ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Tumor Cells ◽  
Immunohistochemical Staining ◽  
Bladder Tumor ◽  
Low Grade ◽  
Elderly Men ◽  
Ki 67 ◽  
Tumor Entity ◽  
Nested Variant ◽  
Nuclear Features

Abstract The nested variant of urothelial carcinoma is a recently described bladder tumor entity with a rare incidence. Two cases of this disease are presented in this report; the patients in both cases were elderly men, with a predominant involvement of the trigone region. Histologically, the tumor cells were arranged in ill-defined nests and had low-grade nuclear features. Both cases had a diffusely infiltrating growth pattern with widespread local disease at cystectomy. Strong immunohistochemical staining for p63 in the neoplastic cells supports the urothelial cell nature of this neoplasm. High p53 and Ki-67 indices of this tumor correlate with the aggressiveness of this subtype.

Correlation analysis of nuclear morphology, cytokeratin and Ki-67 expression of urothelial carcinoma cells

2013 ◽  
Vol 63 (6) ◽  
pp. 311-317 ◽  
Author(s):  
Masayo Shuto ◽  
Kenji Warigaya ◽  
Hiroshi Watanabe ◽  
Michio Shimizu ◽  
Toshio Fukuda ◽  
...  
Keyword(s):  
Correlation Analysis ◽  
Urothelial Carcinoma ◽  
Carcinoma Cells ◽  
Nuclear Morphology ◽  
Ki 67

Genotyping of high-risk human papillomaviruses in p16/Ki-67-positive urothelial carcinoma cells: even a worm will turn

Cytopathology ◽  
2014 ◽  
Vol 26 (2) ◽  
pp. 106-113 ◽  
Author(s):  
A.-S. Advenier ◽  
J.-S. Casalegno ◽  
Y. Mekki ◽  
M. Decaussin-Petrucci ◽  
F. Mège-Lechevallier ◽  
...  
Keyword(s):  
High Risk ◽  
Urothelial Carcinoma ◽  
Human Papillomaviruses ◽  
Carcinoma Cells ◽  
Ki 67

Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6

2020 ◽  
Author(s):  
Steven M Johnson ◽  
Armen Khararjian ◽  
Teklu B Legesse ◽  
Francesca Khani ◽  
Brian D Robinson ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Expression Profiling ◽  
Bladder Tumor ◽  
Molecular Subtype ◽  
Molecular Phenotype ◽  
Bladder Tumors ◽  
Basal Marker ◽  
Cytokeratin 5 ◽  
Nested Variant ◽  
Molecular Phenotypes

Abstract Objectives The nested variant of urothelial carcinoma (NVUC) is a rare bladder tumor that may possess a luminal molecular phenotype. We sought to determine whether a small immunohistochemical (IHC) panel using common surrogates for molecular phenotypes would reliably classify a cohort of pure NVUC cases. Methods IHC staining with a panel composed of markers for basal subtypes (CK5/6, CK14) and luminal subtypes (FOXA1, GATA3) was performed on pure small NVUC cases (n = 23) and 5 large NVUC cases (n = 5). Scoring of IHC stains was performed semiquantitatively. Individual cases were analyzed using previously reported IHC-based surrogates for molecular subtype. Results The phenotype of NVUC was classified as luminal from 60.1% (FOXA1+/CK5/6−) to 100% (GATA3+/CK14−) of cases using composite phenotypes. No cases possessed a basal or squamous cell carcinoma–like phenotype. The majority of small NVUC cases (69.5%) showed subset CK5/6 expression distinctly localized to the basal layers of tumor cell nests. Intratumoral heterogeneity was also noted in CK5/6 (21.7% of small NVUC cases) but no other markers. Conclusions NVUC appears to express markers of both basal and luminal bladder tumors. Definitive gene expression profiling may be valuable to further characterize this unique histologic variant.

Significance of DNA Ploidy and Cell Proliferation in Juvenile Respiratory Papillomatosis

1998 ◽  
Vol 107 (10) ◽  
pp. 815-819 ◽  
Author(s):  
Yoram Stern ◽  
Paul E. Hurtubise ◽  
Robin T. Cotton
Keyword(s):  
Cell Proliferation ◽  
Dna Content ◽  
Dna Ploidy ◽  
Clinical Course ◽  
Clinical Information ◽  
Ki 67 ◽  
Proliferation Activity ◽  
Proliferative Markers ◽  
Patients At Risk ◽  
Aggressive Clinical Course

The clinical course of recurrent respiratory papillomatosis (RRP) in children is variable and unpredictable. At present there is no way to identify patients at risk for aggressive disease. The objective of this study was to evaluate whether DNA ploidy and cell proliferation analyses can predict the clinical course in children with RRP. Two different methods of estimating proliferation activity were compared. Nonembedded papilloma biopsy specimens from 18 pediatric patients were analyzed by flow cytometry providing DNA content with cell cycle analysis. The expression of the proliferative marker Ki-67 in papilloma tissue was quantified by immunohistochemistry. The patients were prospectively observed for 12 to 18 months. DNA content analysis and Ki-67 expression were compared to clinical information regarding number of disease sites, distal tracheobronchial spread, number of recurrences, need for tracheostomy, and disease remission. High S-phase fraction, proliferative index, and Ki-67 expression correlated with an aggressive clinical course. DNA ploidy analysis and immunodetection of proliferative markers may assist in predicting prognosis in children with RRP.

Scattered sarcomatoid urothelial carcinoma cells within MALT lymphoma of the urinary bladder

2016 ◽  
Vol 10 (3) ◽  
pp. 267-270
Author(s):  
Tadashi Terada
Keyword(s):  
T Cells ◽  
B Cells ◽  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Surface Area ◽  
Malt Lymphoma ◽  
Carcinoma Cells ◽  
Low Grade ◽  
Ki 67 ◽  
Non Invasive

Recently the author encountered a peculiar tumour of the bladder consisting of the following three components: MALT lymphoma, scattered poorly cohesive sarcomatoid urothelial carcinoma within MALT lymphoma, and surface non-invasive, low-grade conventional urothelial carcinoma (UC) occurring in a 65-year-old female. A low-power view showed MALT. Meticulous observations revealed a small amount of non-invasive, low-grade conventional UC at the surface area. In addition, meticulous observations identified a small number of cytokeratin-positive, poorly cohesive sarcomatoid UC cells scattered within the MALT lymphoma. The MALT lymphoma was typical. Immunohistochemically, the scattered sarcomatoid cells within the MALT lymphoma were positive for various types of CK, EMA, p53 and Ki-67 (LI = 70%). The MALT lymphoma was composed mainly of B-cells (CD10, CD20, CD23, CD79α, κ-chains and λ-chain), but T-cells positive for CD3, CD4, CD5, CD43 or CD45RO were seen in a very small number. This scattering sarcomatoid UC within MALT lymphoma of bladder has not been reported.

Aggressive Clinical Course

2020 ◽  
Author(s):  
Keyword(s):  
Clinical Course ◽  
Aggressive Clinical Course

Developing a nomogram for predicting intravesical recurrence after radical nephroureterectomy: a retrospective cohort study of mainland Chinese patients

2021 ◽  
Author(s):  
Shicong Lai ◽  
Xingbo Long ◽  
Pengjie Wu ◽  
Jianyong Liu ◽  
Samuel Seery ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Cox Regression ◽  
Upper Tract Urothelial Carcinoma ◽  
Chinese Patients ◽  
Clinicopathological Parameters ◽  
Radical Nephroureterectomy ◽  
Ki 67 ◽  
Data Set ◽  
Mainland Chinese ◽  
Upper Tract

Abstract Objective To evaluate the role of Ki-67 in predicting subsequent intravesical recurrence following radical nephroureterectomy and to develop a predictive nomogram for upper tract urothelial carcinoma patients. Methods This retrospective analysis involved 489 upper tract urothelial carcinoma patients who underwent radical nephroureterectomy with bladder cuff excision. The data set was randomly split into a training cohort of 293 patients and a validation cohort of 196 patients. Immunohistochemical analysis was used to assess the immunoreactivity of the biomarker Ki-67 in the tumor tissues. A multivariable Cox regression model was utilized to identify independent intravesical recurrence predictors after radical nephroureterectomy before constructing a nomographic model. Predictive accuracy was quantified using time-dependent receiver operating characteristic curve. Decision curve analysis was performed to evaluate the clinical benefit of models. Results With a median follow-up of 54 months, intravesical recurrence developed in 28.2% of this sample (n = 137). Tumor location, multifocality, pathological T stage, surgical approach, bladder cancer history and Ki-67 expression levels were independently associated with intravesical recurrence (all P < 0.05). The full model, which intercalated Ki-67 with traditional clinicopathological parameters, outperformed both the basic model and Xylinas’ model in terms of discriminative capacity (all P < 0.05). Decision-making analysis suggests that the more comprehensive model can also improve patients’ net benefit. Conclusions This new model, which intercalates the Ki-67 biomarker with traditional clinicopathological factors, appears to be more sensitive than nomograms previously tested across mainland Chinese populations. The findings suggest that Ki-67 could be useful for determining risk-stratified surveillance protocols following radical nephroureterectomy and in generating an individualized strategy based around intravesical recurrence predictions.

scholarly journals The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dexin Shen ◽  
Yayun Fang ◽  
Fenfang Zhou ◽  
Zhao Deng ◽  
Kaiyu Qian ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Urothelial Carcinoma ◽  
Carcinoma Cells ◽  
Expression Level ◽  
Tumor Cell Growth ◽  
Migration Ability ◽  
Bladder Urothelial Carcinoma ◽  
Related Proteins

Abstract Background CDCA3 is an important component of the E3 ligase complex with SKP1 and CUL1, which could regulate the progress of cell mitosis. CDCA3 has been widely identified as a proto-oncogene in multiple human cancers, however, its role in promoting human bladder urothelial carcinoma has not been fully elucidated. Methods Bioinformatic methods were used to analyze the expression level of CDCA3 in human bladder urothelial carcinoma tissues and the relationship between its expression level and key clinical characteristics. In vitro studies were performed to validate the specific functions of CDCA3 in regulating cell proliferation, cell migration and cell cycle process. Alterations of related proteins was investigated by western blot assays. In vivo studies were constructed to validate whether silencing CDCA3 could inhibit the proliferation rate in mice model. Results Bioinformatic analysis revealed that CDCA3 was significantly up-regulated in bladder urothelial carcinoma samples and was related to key clinical characteristics, such as tumor grade and metastasis. Moreover, patients who had higher expression level of CDCA3 tend to show a shorter life span. In vitro studies revealed that silencing CDCA3 could impair the migration ability of tumor cells via down-regulating EMT-related proteins such as MMP9 and Vimentin and inhibit tumor cell growth via arresting cells in the G1 cell cycle phase through regulating cell cycle related proteins like p21. In vivo study confirmed that silencing CDCA3 could inhibit the proliferation of bladder urothelial carcinoma cells. Conclusions CDCA3 is an important oncogene that could strengthen the migration ability of bladder urothelial carcinoma cells and accelerate tumor cell growth via regulating cell cycle progress and is a potential biomarker of bladder urothelial carcinoma.

Mutations of CARD15 gene in Crohn's disease patients are more frequent in ASCA-positive with more aggressive clinical course. An Ig-IBD study

2003 ◽  
Vol 124 (4) ◽  
pp. A376
Author(s):  
Vito Annese ◽  
Arnaldo Andreoli ◽  
Bollani Serafina ◽  
Fabiana Castiglione ◽  
Mario Cottone ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Course ◽  
Card15 Gene ◽  
Aggressive Clinical Course
Sign in / Sign up

Export Citation Format

Share Document